ClinicalTrials.gg
RecruitingNCT06865885SOLVE-LDL-CUpdated Nov 10, 2026

LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering

A Phase 4 interventional study of Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL in Drug Interactions, Primary Prevention and Cardiometabolic Syndrome, sponsored by University of California, San Diego. Recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by University of California, San Diego · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Nov 10, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 578 studies in Metabolic Syndrome with a site in United States — 62 open to participants now, 84 under way, 3 of them phase 3. Metabolic Syndrome · United States.

Planned enrollment
117th of 490
100 · median 48
Started
2025
with 17 others
Phase 4
44 of 578
5 open now
Primary completion
2028-06
later than 56 of 82 live
Registered
549th of 578
by date
Lead sponsor
9 of 578
University of California, San Diego

Among the 578 studies in Metabolic Syndrome with a site in United States, this one is the 117th largest by planned enrollment of the 490 interventional ones that give a count, is one of 18 that started in 2025, is one of 44 in phase 4, reaches primary completion later than 56 of the 82 other live ones, and was the 549th registered.

Metabolic Syndrome

2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

62 of the 578 studies in Metabolic Syndrome with a site in United States are open now. Recruiting first, the newest first:

56 more — sign in →

All 62 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 578 studies in Metabolic Syndrome with a site in United States, or all of them as a file.
02

Study summary

Polypharmacy and drug-drug interactions often limit statin optimization, including in a population of patients prescribed cytochrome P3A4 inhibitors such as, immunosuppressive agents, protease inhibitors, and antifungals. These patients frequently have autoimmune conditions or rheumatologic disorders that require complex drug regimens and are often on low-dose statin therapy or no statin at all, resulting in suboptimal LDL levels despite increased cardiovascular (CV) risk.

There is an unmet clinical need to improve LDL levels in this vulnerable patient population, which faces increased CV risk due to underlying conditions that also contribute to polypharmacy and multiple drug-drug interactions. This study is a randomized, open-label trial evaluating subcutaneous inclisiran plus standard of care for LDL-C lowering in high-risk primary prevention patients with multiple comorbidities (e.g., type II diabetes, liver disease, chronic kidney disease, autoimmune disease, solid-organ transplant, etc.) who are taking five or more medications in which drug-drug interactions may prevent optimization of statin therapy.

Read the detailed description

This is an investigator-initiated, single-site, open-label, randomized trial. The investigators will enroll up to 100 high-risk primary prevention patients with at least one comorbidity and an indication for additional lipid control (such as Type II diabetes with A1c ≤ 8.5%, subclinical atherosclerosis, or increased 10-year ASCVD risk). Patients will be randomized 1:1 to the inclisiran arm (n ≥ 50) with standard of care or standard of care alone (n ≥ 50).

The study will consist of five study visits (screening, baseline, 3 months, 9 months, and 12 months). Patients in the inclisiran arm will receive a subcutaneous injection of inclisiran 284 mg for three doses (baseline, 3 months, and 9 months following randomization) as add-on therapy. LDL-C (the primary endpoint) along with other biomarkers will be measured at screening, baseline (inclisiran dose #1), 3 months (inclisiran dose #2), 9 months (inclisiran dose #3), and 12 months (labs only). Patients will also undergo medical history and medication review at each visit. Surveys will be completed at each visit during the study period.

Patients in the control arm (standard of care) will continue with their current lipid-lowering therapy. No adjustments will be made to lipid-lowering therapy during the course of the study. Participants will be aware of the group to which they have been randomized.

The primary objective is to determine the efficacy of inclisiran for LDL-C lowering in high-risk primary prevention patients with multiple comorbidities (e.g., type II diabetes, autoimmune disease, liver disease, chronic kidney disease, solid-organ transplant) who are taking five or more medications in which drug-drug interactions may prevent optimization of statin therapy.

03

Conditions studied

  • Drug Interactions
  • Primary Prevention
  • Cardiometabolic Syndrome
  • LDL-Cholersterol Lowering
  • Polypharmacy

Browse trials for

Keywords

  • Statin intolerance
  • drug drug interaction
  • inclisiran
  • LDL-Cholesterol
  • polypharmacy
  • multiple comorbidities
04

Who can participate

The criteria were revised on the registry on Nov 10, 2026. See what changed

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible to participate in this study, individuals must meet all of the following criteria:

  1. Provide signed and dated form.
  2. Are willing to comply with all study procedures and availability for the duration of the study including the potential randomization to injections, as stated by the participant and assessed by study staff.
  3. Are ≥ 18 and ≤ 85 years of age with the ability to consent for themselves.
  4. Take 5 or more medications at the time of enrollment (any type of medication). This includes prescription drugs, as well as over-the-counter drugs or supplements recommended by a healthcare provider, in line with the WHO definition of polypharmacy.
  5. Meet at least one of criteria a, b, or c:

    1. Elevated 10-year ASCVD risk score ≥7.5% based on the ACC/AHA Pooled Cohort ASCVD Risk Estimator Plus tool OR PREVENT-ASCVD 10-Year Risk Estimate ≥ 10% (https://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/) Or
    2. Evidence of subclinical atherosclerosis:

      • calcification in any vascular bed, including coronary arteries, aorta
      • calcification of cardiac valves
      • breast calcification
      • carotid plaque that is not hemodynamically significant Or
    3. Type II diabetes with less than 8.5.
  6. Take maximally tolerated dose of statin therapy (for patients that have documented statin intolerance or , this can be no statin) and have suboptimal LDL levels (LDL ≥ 70 mg/dL or non-HDL ≥ 100 mg/dL based on current treatment guidelines).
  7. Are on stable lipid-lowering therapy for at least 4 weeks prior to screening. Patients can also take other non-PCSK9i lipid-lowering therapies, such as ezetimibe, bempedoic acid, icosapent ethyl, and fibrates.
  8. May have potential drug-drug interactions that may limit statin dose or up-titration.
  9. Agree to adhere to lifestyle considerations (see Section 5.3) throughout study duration.

Exclusion criteria

Exclusion Criteria:

Individuals who meet any of the following criteria will be excluded from participation in this study:

  1. Have a history of ASCVD, defined as history of myocardial infarction, atherosclerotic ischemic stroke, (TIA) of atherosclerotic ischemic origin, coronary artery bypass graft (CABG), coronary/carotid/peripheral artery/aortic stent for atherosclerotic disease, or peripheral artery disease diagnosed via imaging or ankle-brachial index).

    • For heart transplant recipients, history of myocardial infarction, CABG, or coronary artery stenting is only exclusionary after most recent heart transplant.
    • Non-atherosclerotic ischemic strokes or TIAs identified as cardioembolic or attributed to hypercoagulability or non-atherosclerotic vasculopathy are NOT exclusionary.
  2. Are pregnant, nursing, or trying to conceive.
  3. Are currently taking PCSK9 inhibitors (evolocumab, alirocumab) or are already on inclisiran. If any prior exposure to evolocumab or alirocumab, the last dose should have been at least 12 weeks prior to study enrollment. If any prior exposure to inclisiran, the last dose should have been at least 6 months prior to study enrollment.
  4. Have a coronary artery calcium score ≥ 300 as these patients are considered secondary prevention patients.
  5. Are currently enrolled in medical research judged not to be scientifically or medically compatible with this study as determined at the discretion of the PI.
  6. Have any other medical condition(s) or take any treatment(s) deemed by the investigator to pose a risk to patient safety or interfere with study evaluation, procedures, or completion.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • No intervention
    Standard of Care, no intervention

    Patients will continue the standard of care for lipid lowering as deemed appropriate by their medical team, no changes to lipid lowering therapy are permitted during the study.

  • Active comparator
    Inclisiran Arm

    Patients in the intervention arm will be treated with a subcutaneous injection of inclisiran 284mg for three doses (baseline visit, 3 month, then 9 month visit) as add-on therapy to the standard of care for lipid lowering as determined by their medical team.

    Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

Interventions

  • DrugInclisiranStudies of InclisiranInclisiran pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The intervention arm will receive subcutaneous injection of inclisiran 284mg at the baseline visit, 3 month and 9 month visit.

06

What researchers measure

Primary outcomes

  1. Change of LDL-Cholesterol

    Percent Change in LDL-C from baseline to month 12 of treatment with inclisiran as add on to background lipid-lowering therapy that includes maximally tolerated statin.

    Time frame: 12 months

Secondary outcomes

  1. Change in Atherogenic Lipid Burden

    Absolute and percent change in LDL particle number, apo B, non-HDL, and small LDL particle number, lipoprotein(a), from baseline (Day 1) to month 12 of treatment with inclisiran

    Time frame: 12 months

Other outcomes

  1. Patient-Reported Experience

    Patient-reported outcomes and experiences determined by surveys at each visit (the Standardized Treatment Satisfaction Questionnaire for Medication and study-specific inclisiran satisfaction questionnaire).

    Time frame: 12 months

  2. Incidence of Adverse Events

    Incidence of adverse events occurring during treatment with inclisiran.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Wright RS, Ray KK, Raal FJ, Kallend DG, Jaros M, Koenig W, Leiter LA, Landmesser U, Schwartz GG, Friedman A, Wijngaard PLJ, Garcia Conde L, Kastelein JJP; ORION Phase III Investigators. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. J Am Coll Cardiol. 2021 Mar 9;77(9):1182-1193. doi: 10.1016/j.jacc.2020.12.058. PubMed 33663735 ↗
  • Budoff MJ, Kinninger A, Gransar H, Achenbach S, Al-Mallah M, Bax JJ, Berman DS, Cademartiri F, Callister TQ, Chang HJ, Chow BJW, Cury RC, Feuchtner G, Hadamitzky M, Hausleiter J, Kaufmann PA, Leipsic J, Lin FY, Kim YJ, Marques H, Pontone G, Rubinshtein R, Shaw LJ, Villines TC, Min JK; CONFIRM Investigators. When Does a Calcium Score Equate to Secondary Prevention?: Insights From the Multinational CONFIRM Registry. JACC Cardiovasc Imaging. 2023 Sep;16(9):1181-1189. doi: 10.1016/j.jcmg.2023.03.008. Epub 2023 May 24. PubMed 37227328 ↗
  • American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024. Diabetes Care. 2024 Jan 1;47(Suppl 1):S179-S218. doi: 10.2337/dc24-S010. PubMed 38078592 ↗
  • Iribarren C, Chandra M, Lee C, Sanchez G, Sam DL, Azamian FF, Cho HM, Ding H, Wong ND, Molloi S. Breast Arterial Calcification: a Novel Cardiovascular Risk Enhancer Among Postmenopausal Women. Circ Cardiovasc Imaging. 2022 Mar;15(3):e013526. doi: 10.1161/CIRCIMAGING.121.013526. Epub 2022 Mar 15. PubMed 35290077 ↗
  • Fox CS, Vasan RS, Parise H, Levy D, O'Donnell CJ, D'Agostino RB, Benjamin EJ; Framingham Heart Study. Mitral annular calcification predicts cardiovascular morbidity and mortality: the Framingham Heart Study. Circulation. 2003 Mar 25;107(11):1492-6. doi: 10.1161/01.cir.0000058168.26163.bc. PubMed 12654605 ↗
  • Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med. 1999 Jul 15;341(3):142-7. doi: 10.1056/NEJM199907153410302. PubMed 10403851 ↗
  • Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ, Kastelein JJP; ORION-10 and ORION-11 Investigators. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020 Apr 16;382(16):1507-1519. doi: 10.1056/NEJMoa1912387. Epub 2020 Mar 18. PubMed 32187462 ↗
  • Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, Wijngaard PLJ, Curcio D, Jaros MJ, Leiter LA, Kastelein JJP; ORION-9 Investigators. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020 Apr 16;382(16):1520-1530. doi: 10.1056/NEJMoa1913805. Epub 2020 Mar 18. PubMed 32197277 ↗
  • Wiggins BS, Saseen JJ, Page RL 2nd, Reed BN, Sneed K, Kostis JB, Lanfear D, Virani S, Morris PB; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Hypertension; Council on Quality of Care and Outcomes Research; and Council on Functional Genomics and Translational Biology. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2016 Nov 22;134(21):e468-e495. doi: 10.1161/CIR.0000000000000456. Epub 2016 Oct 17. No abstract available. PubMed 27754879 ↗
  • Hughes JE, Waldron C, Bennett KE, Cahir C. Prevalence of Drug-Drug Interactions in Older Community-Dwelling Individuals: A Systematic Review and Meta-analysis. Drugs Aging. 2023 Feb;40(2):117-134. doi: 10.1007/s40266-022-01001-5. Epub 2023 Jan 24. PubMed 36692678 ↗
  • Moran CA, Collins LF, Beydoun N, Mehta PK, Fatade Y, Isiadinso I, Lewis TT, Weber B, Goldstein J, Ofotokun I, Quyyumi A, Choi MY, Titanji K, Lahiri CD. Cardiovascular Implications of Immune Disorders in Women. Circ Res. 2022 Feb 18;130(4):593-610. doi: 10.1161/CIRCRESAHA.121.319877. Epub 2022 Feb 17. PubMed 35175848 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) is not expected to be shared due to privacy concerns, institutional policies, and regulatory considerations. However, the Principal Investigator may determine that certain de-identified data may be shared with other researchers on a case-by-case basis, subject to appropriate approvals and data use agreements.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jun 2028, 37 months after the start.

Of 32 phase 4 interventional studies under Metabolic Syndrome, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 37 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Dec 2026 → Jun 2028 and completion Mar 2027 → Sep 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2025
First posted
Mar 10, 2025
StartActual
Apr 2, 2025
Primary completionEst.
Jun 1, 2028was Dec 2026
CompletionEst.
Sep 1, 2028was Mar 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 30, 2026→Jun 1, 2028
Nov 10, 2026
Study completion
Mar 31, 2027→Sep 1, 2028
Nov 10, 2026
Eligibility
7 inclusion criteria edited, 10 added, 8 removed; 9 exclusion criteria added, 10 removed
What changed in the criteria
Inclusion criteria
  • AddedTo be eligible to participate in this study, individuals must meet all of the following criteria:
  • EditedProvision ofProvide signed and dated informed consent form.
  • EditedStated willingnessAre willing to comply with all study procedures and availability for the duration of the study, including the potential randomization to injections, as stated by the participant and assessed by study staff.
  • RemovedAge >18 and <85 years and able to provide self-consent.
  • RemovedTaking five or more prescription drugs at the time of enrollment, of any type.
  • AddedAre ≥ 18 and ≤ 85 years of age with the ability to consent for themselves.
  • AddedTake 5 or more medications at the time of enrollment (any type of medication). This includes prescription drugs, as well as over-the-counter drugs or supplements recommended by a healthcare provider, in line with the WHO definition of polypharmacy.
  • EditedMeetsMeet at least one of the following criteriacriteria a, b, or c:
  • EditedElevated 10-year ASCVD risk score ≥7.5% (based on the ACC/AHA Pooled Cohort ASCVD Risk Estimator Plus tool OR PREVENT-ASCVD 10-Year Risk Estimate ≥ 10% (https://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/). Or
  • EditedEvidence of subclinical atherosclerosis including:
  • EditedCalcificationcalcification in any vascular bed, including coronary arteries and, aorta. Calcification of cardiac valves. Breast calcification. Carotid plaque that is not hemodynamically significant.
  • Removedo Type II diabetes on a stable medical regimen with HbA1c <8.5%. Per American Diabetes Association guidelines, patients with Type II diabetes aged 40-75 years should be on a moderate-intensity statin.
  • RemovedPatients with documented partial or complete statin intolerance are eligible for enrollment.
  • RemovedOn maximally tolerated statin therapy (which can be no statin for patients with documented intolerance) and have suboptimal LDL levels:
  • RemovedFor patients with Type II diabetes: LDL >70 mg/dL or non-HDL >120 mg/dL.
  • RemovedFor other patients: LDL >90 mg/dL or non-HDL >120 mg/dL.
  • RemovedWilling to adhere to the randomized study regimen, including subcutaneous injection of inclisiran.
  • Addedcalcification of cardiac valves
  • Addedbreast calcification
  • Addedcarotid plaque that is not hemodynamically significant Or
  • AddedType II diabetes with HbA1c less than 8.5.
  • AddedTake maximally tolerated dose of statin therapy (for patients that have documented statin intolerance or contraindication, this can be no statin) and have suboptimal LDL levels (LDL ≥ 70 mg/dL or non-HDL ≥ 100 mg/dL based on current treatment guidelines).
  • AddedAre on stable lipid-lowering therapy for at least 4 weeks prior to screening. Patients can also take other non-PCSK9i lipid-lowering therapies, such as ezetimibe, bempedoic acid, icosapent ethyl, and fibrates.
  • AddedMay have potential drug-drug interactions that may limit statin dose or up-titration.
  • EditedAgreementAgree to adhere to lifestyle considerations (see Section 5.3) throughout the study duration.
Exclusion criteria
  • RemovedPrior or current use of inclisiran.
  • RemovedKnown hypersensitivity or allergy to inclisiran or its components.
  • RemovedActive liver disease or unexplained persistent elevations in liver enzymes (ALT or AST >3x upper limit of normal).
  • RemovedHistory of rhabdomyolysis or severe muscle-related statin intolerance.
  • RemovedUncontrolled diabetes (HbA1c >8.5%).
  • RemovedActive malignancy requiring systemic therapy.
  • RemovedRecent major cardiovascular event (myocardial infarction, stroke, or hospitalization for unstable angina) within the past 3 months.
  • RemovedHistory of organ transplant other than solid-organ transplant.
  • RemovedPregnancy or breastfeeding.
  • RemovedAny condition that, in the opinion of the investigator, would make participation unsafe or interfere with study procedures.
  • AddedIndividuals who meet any of the following criteria will be excluded from participation in this study:
  • AddedHave a history of ASCVD, defined as history of myocardial infarction, atherosclerotic ischemic stroke, transient ischemic attack (TIA) of atherosclerotic ischemic origin, coronary artery bypass graft (CABG), coronary/carotid/peripheral artery/aortic stent for atherosclerotic disease, or peripheral artery disease diagnosed via imaging or ankle-brachial index).
  • AddedFor heart transplant recipients, history of myocardial infarction, CABG, or coronary artery stenting is only exclusionary after most recent heart transplant.
  • AddedNon-atherosclerotic ischemic strokes or TIAs identified as cardioembolic or attributed to hypercoagulability or non-atherosclerotic vasculopathy are NOT exclusionary.
  • AddedAre pregnant, nursing, or trying to conceive.

…and 4 more changes, on the record history on ClinicalTrials.gov ↗

Nov 10, 2026
Secondary outcomes
2 description edited
What changed in the outcomes
  • DescriptionChange in Atherogenic Lipid Burden: how it is measured was reworded
  • Descriptionother outcomePatient-Reported Experience: how it is measured was reworded
Nov 10, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • UC San Diego Altman Clinical and Translational Research Institute · La Jolla, United StatesContact m•••@health.ucsd.edu · •••8234→s•••@health.ucsd.edu · •••2715Contact l•••@health.ucsd.edu · •••2406→g•••@health.ucsd.edu · •••2342
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion Dec 30, 2026→Jun 1, 2028
    Study completion Mar 31, 2027→Sep 1, 2028
    Eligibility 7 inclusion criteria edited, 10 added, 8 removed; 9 exclusion criteria added, 10 removed
    What changed in the criteria
    Inclusion criteria
    • AddedTo be eligible to participate in this study, individuals must meet all of the following criteria:
    • EditedProvision ofProvide signed and dated informed consent form.
    • EditedStated willingnessAre willing to comply with all study procedures and availability for the duration of the study, including the potential randomization to injections, as stated by the participant and assessed by study staff.
    • RemovedAge >18 and <85 years and able to provide self-consent.
    • RemovedTaking five or more prescription drugs at the time of enrollment, of any type.
    • AddedAre ≥ 18 and ≤ 85 years of age with the ability to consent for themselves.
    • AddedTake 5 or more medications at the time of enrollment (any type of medication). This includes prescription drugs, as well as over-the-counter drugs or supplements recommended by a healthcare provider, in line with the WHO definition of polypharmacy.
    • EditedMeetsMeet at least one of the following criteriacriteria a, b, or c:
    • EditedElevated 10-year ASCVD risk score ≥7.5% (based on the ACC/AHA Pooled Cohort ASCVD Risk Estimator Plus tool OR PREVENT-ASCVD 10-Year Risk Estimate ≥ 10% (https://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/). Or
    • EditedEvidence of subclinical atherosclerosis including:
    • EditedCalcificationcalcification in any vascular bed, including coronary arteries and, aorta. Calcification of cardiac valves. Breast calcification. Carotid plaque that is not hemodynamically significant.
    • Removedo Type II diabetes on a stable medical regimen with HbA1c <8.5%. Per American Diabetes Association guidelines, patients with Type II diabetes aged 40-75 years should be on a moderate-intensity statin.
    • RemovedPatients with documented partial or complete statin intolerance are eligible for enrollment.
    • RemovedOn maximally tolerated statin therapy (which can be no statin for patients with documented intolerance) and have suboptimal LDL levels:
    • RemovedFor patients with Type II diabetes: LDL >70 mg/dL or non-HDL >120 mg/dL.
    • RemovedFor other patients: LDL >90 mg/dL or non-HDL >120 mg/dL.
    • RemovedWilling to adhere to the randomized study regimen, including subcutaneous injection of inclisiran.
    • Addedcalcification of cardiac valves
    • Addedbreast calcification
    • Addedcarotid plaque that is not hemodynamically significant Or
    • AddedType II diabetes with HbA1c less than 8.5.
    • AddedTake maximally tolerated dose of statin therapy (for patients that have documented statin intolerance or contraindication, this can be no statin) and have suboptimal LDL levels (LDL ≥ 70 mg/dL or non-HDL ≥ 100 mg/dL based on current treatment guidelines).
    • AddedAre on stable lipid-lowering therapy for at least 4 weeks prior to screening. Patients can also take other non-PCSK9i lipid-lowering therapies, such as ezetimibe, bempedoic acid, icosapent ethyl, and fibrates.
    • AddedMay have potential drug-drug interactions that may limit statin dose or up-titration.
    • EditedAgreementAgree to adhere to lifestyle considerations (see Section 5.3) throughout the study duration.
    Exclusion criteria
    • RemovedPrior or current use of inclisiran.
    • RemovedKnown hypersensitivity or allergy to inclisiran or its components.
    • RemovedActive liver disease or unexplained persistent elevations in liver enzymes (ALT or AST >3x upper limit of normal).
    • RemovedHistory of rhabdomyolysis or severe muscle-related statin intolerance.
    • RemovedUncontrolled diabetes (HbA1c >8.5%).
    • RemovedActive malignancy requiring systemic therapy.
    • RemovedRecent major cardiovascular event (myocardial infarction, stroke, or hospitalization for unstable angina) within the past 3 months.
    • RemovedHistory of organ transplant other than solid-organ transplant.
    • RemovedPregnancy or breastfeeding.
    • RemovedAny condition that, in the opinion of the investigator, would make participation unsafe or interfere with study procedures.
    • AddedIndividuals who meet any of the following criteria will be excluded from participation in this study:
    • AddedHave a history of ASCVD, defined as history of myocardial infarction, atherosclerotic ischemic stroke, transient ischemic attack (TIA) of atherosclerotic ischemic origin, coronary artery bypass graft (CABG), coronary/carotid/peripheral artery/aortic stent for atherosclerotic disease, or peripheral artery disease diagnosed via imaging or ankle-brachial index).
    • AddedFor heart transplant recipients, history of myocardial infarction, CABG, or coronary artery stenting is only exclusionary after most recent heart transplant.
    • AddedNon-atherosclerotic ischemic strokes or TIAs identified as cardioembolic or attributed to hypercoagulability or non-atherosclerotic vasculopathy are NOT exclusionary.
    • AddedAre pregnant, nursing, or trying to conceive.

    …and 4 more changes, on the record history on ClinicalTrials.gov ↗

    Secondary outcomes 2 description edited
    What changed in the outcomes
    • DescriptionChange in Atherogenic Lipid Burden: how it is measured was reworded
    • Descriptionother outcomePatient-Reported Experience: how it is measured was reworded
    Site contacts Changed at 1 site. See the sites
    Show the site
    • UC San Diego Altman Clinical and Translational Research Institute · La Jolla, United StatesContact m•••@health.ucsd.edu · •••8234→s•••@health.ucsd.edu · •••2715Contact l•••@health.ucsd.edu · •••2406→g•••@health.ucsd.edu · •••2342
    + 5 other changes: identifiers, verification date, description, conditions and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06865885
Collaborators
Novartis
Responsible party
Pam Taub, MD (Professor of Medicine, Directior of Preventative Cardiology, University of California, San Diego) — Principal investigator
First posted
Mar 10, 2025
Start date
Apr 2, 2025
Primary completion
Jun 1, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Nov 10, 2026

Study contacts

Pam Taub, MD
Contact
ptaub@health.ucsd.edu
858-657-8530
Antoinette S Birs, MD
Contact
abirs@health.ucsd.edu
5612817745
Michael Wilkinson, MD
study director · University of California, San Diego
Eric D Adler, MD
study chair · University of California, San Diego
Pam Taub, MD
principal investigator · University of California, San Diego
Antoinette Birs, MD
study director · University of California, San Diego
Edward Duran, MD
study director · University of California, San Diego

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inclisiran

Start the discussion